López-Calleja A I, Morilla Morales E, Nuñez Medina R, Fernández Esgueva M, Sahagún Pareja J, García-Lechuz Moya J M, Ferrer Cerón I, Viñuelas Bayon J, Rezusta López A
Ana Isabel López-Calleja, Servicio de Microbiología, Hospital Universitario Miguel Servet. IIS Aragón. 3ª planta Edificio de Consultas Externas - c/ Padre Arrupe s/n, 50009 Zaragoza, Spain.
Rev Esp Quimioter. 2019 Feb;32(1):68-72. Epub 2018 Dec 14.
Our objective was to evaluate the in vitro activity of ceftolozane-tazobactam against multidrug resistant (MDR) and extensively drug-resistant (XDR) non metallo-β-lactamase producing Pseudomonas aeruginosa clinical isolates at Hospital Universitario Miguel Servet (Zaragoza, Spain) from February 2016 to October 2017.
We evaluated the in vitro activity of ceftolozane-tazobactam and other antipseudomonal antibiotics against 12 MDR and 117 XDR non metallo-β-lactamase producing P. aeruginosa isolates. Ceftolozane-tazobactam minimal inhibitory concentrations (MICs) were determined by MIC gradient diffusion test strip.
Among the 129 MDR/XDR isolates included, 119 (92.2%) were susceptible to ceftolozane-tazobactam, and ten (7.8%) were resistant. MIC50 was 2 mg/L, and MIC90 4 mg/L. Ceftolozane-tazobactam was the second most active antibiotic after colistin, overtaking amikacin.
Ceftolozane-tazobactam is a valuable treatment option for MDR and XDR P. aeruginosa infections in our setting.
我们的目的是评估2016年2月至2017年10月在西班牙萨拉戈萨米格尔·塞维特大学医院,头孢他啶-阿维巴坦对多重耐药(MDR)和广泛耐药(XDR)、不产金属β-内酰胺酶的铜绿假单胞菌临床分离株的体外活性。
我们评估了头孢他啶-阿维巴坦和其他抗假单胞菌抗生素对12株MDR和117株XDR、不产金属β-内酰胺酶的铜绿假单胞菌分离株的体外活性。通过MIC梯度扩散试验条测定头孢他啶-阿维巴坦的最低抑菌浓度(MICs)。
在纳入的129株MDR/XDR分离株中,119株(92.2%)对头孢他啶-阿维巴坦敏感,10株(7.8%)耐药。MIC50为2mg/L,MIC90为4mg/L。头孢他啶-阿维巴坦是继黏菌素之后活性第二高的抗生素,超过了阿米卡星。
在我们的研究环境中,头孢他啶-阿维巴坦是治疗MDR和XDR铜绿假单胞菌感染的一个有价值的治疗选择。